Eli Lilly’s Mounjaro has launched in India. Approved by CDSCO, it promises significant weight loss and blood sugar control. However, concerns remain over certain side effects.

Chemically known as tirzepatide, Mounjaro is currently sold in the UK and Europe under the same brand name for both diabetes ...

Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...

While the clinical dementia findings did not reach statistical significance, they were the first to provide a hint that early ...

British investment firm SV Health Investors has secured $250 million to go toward the development of first-in-class ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a new study. The ...

GLP-1 agonists remain out of reach for many due to high costs, leading some patients to turn to unsafe compounded versions ...

Eli Lilly (NYSE: LLY) has been around for almost 150 years, finding ways to innovate and grow. Today, it's the most valuable ...

Circular Genomics, originally founded in New Mexico, and who specializes in circular RNA (circRNA) biomarkers for precision ...

Compounding pharmacies have been allowed to essentially make a cheaper version of Eli Lilly's Zepbound, but they have to stop ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...